Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2017

Open Access 01-12-2017 | Research

Cinchonine induces apoptosis of HeLa and A549 cells through targeting TRAF6

Authors: Yonghao Qi, Ambara R. Pradipta, Miao Li, Xuan Zhao, Lulu Lu, Xuegang Fu, Jing Wei, Richard P. Hsung, Katsunori Tanaka, Lijun Zhou

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Login to get access

Abstract

Background

Cancer cells are known to over-express TRAF6 that is critical for both AKT and TAK1 activations. The Really Interesting New Gene (RING) domain of TRAF6 is believed to be responsible for the E3 ligase activity, ZINC fingers of TRAF6 provide critical support for the activity of the RING domain which is critical for both AKT and TAK1 activations.

Methods

We employed computational docking program to identify small molecules that could effectively and competitively bind with the RING domain of TRAF6, which is believed to be responsible for its E3 ligase activity. MTT assay and flow cytometry were employed to analyze apoptosis of cancer cells. Signaling pathways were detected using immunoprecipitation and western blotting, and immunofluorescence was pursued to assess the nature of binding of cinchonine to TRAF6. We also performed animal experiments to test effect of cinchonine in vivo.

Results

Cinchonine, a naturally occurring Cinchona alkaloid identified from the docking study, could bind to TRAF6 in HeLa and A549 cells and induce apoptosis of these cancer cells. We found that AKT ubiquitination and phosphorylation as well as phosphorylation of TAK1 were decreased. These activities would lead to subsequent suppression anti-apoptotic protein Bcl-2, while elevating pro-apoptotic protein Bax. Immunofluorescence staining unambiguously demonstrated the binding of cinchonine specifically at the RING domain of TRAF6 in cells, thereby validating the computational modeling. Animal experiments showed that cinchonine could suppress tumor growth in mice without showing significant acute toxicity.

Conclusion

These investigations suggest that through competitive binding with the RING domain of TRAF6, cinchonine could induce apoptosis via inhibiting AKT and TAK1 signaling pathways.
Appendix
Available only for authorised users
Literature
1.
go back to reference Inoue J, et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res. 2000;254(1):14–24.CrossRefPubMed Inoue J, et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res. 2000;254(1):14–24.CrossRefPubMed
3.
go back to reference Wang C, et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001;412(6844):346–51.CrossRefPubMed Wang C, et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001;412(6844):346–51.CrossRefPubMed
4.
go back to reference Bilir C, et al. Increased serum tumor necrosis factor receptor-associated factor-6 expression in patients with non-metastatic triple-negative breast cancer. Oncol Lett. 2015;9(6):2819–24.PubMedPubMedCentral Bilir C, et al. Increased serum tumor necrosis factor receptor-associated factor-6 expression in patients with non-metastatic triple-negative breast cancer. Oncol Lett. 2015;9(6):2819–24.PubMedPubMedCentral
5.
go back to reference Han QQ, et al. TRAF6 promoted the metastasis of esophageal squamous cell carcinoma. Tumour Biol. 2014;35(1):715–21.CrossRefPubMed Han QQ, et al. TRAF6 promoted the metastasis of esophageal squamous cell carcinoma. Tumour Biol. 2014;35(1):715–21.CrossRefPubMed
6.
go back to reference Meng Q, et al. TRAF6 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. Mol Cell Biochem. 2012;371(1–2):177–86.CrossRefPubMed Meng Q, et al. TRAF6 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. Mol Cell Biochem. 2012;371(1–2):177–86.CrossRefPubMed
7.
go back to reference Sun H, et al. TRAF6 is upregulated in colon cancer and promotes proliferation of colon cancer cells. Int J Biochem Cell Biol. 2014;53:195–201.CrossRefPubMed Sun H, et al. TRAF6 is upregulated in colon cancer and promotes proliferation of colon cancer cells. Int J Biochem Cell Biol. 2014;53:195–201.CrossRefPubMed
8.
go back to reference Zhang XL, et al. Expression of tumor necrosis factor receptor-associated factor 6 in lung cancer tissues. Asian Pac J Cancer Prev. 2014;15(24):10591–6.CrossRefPubMed Zhang XL, et al. Expression of tumor necrosis factor receptor-associated factor 6 in lung cancer tissues. Asian Pac J Cancer Prev. 2014;15(24):10591–6.CrossRefPubMed
9.
go back to reference Zhang P, et al. TNF receptor-associated factor 6 regulates proliferation, apoptosis, and invasion of glioma cells. Mol Cell Biochem. 2013;377(1–2):87–96. Zhang P, et al. TNF receptor-associated factor 6 regulates proliferation, apoptosis, and invasion of glioma cells. Mol Cell Biochem. 2013;377(1–2):87–96.
10.
go back to reference Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family Scaffold molecules for cytokine receptors, kinases and their regulator. Cell Signal. 2001;13(6):389–400.CrossRefPubMed Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family Scaffold molecules for cytokine receptors, kinases and their regulator. Cell Signal. 2001;13(6):389–400.CrossRefPubMed
12.
go back to reference Lamothe B, et al. The RING domain and first zinc finger of TRAF6 coordinate signaling by interleukin-1, lipopolysaccharide, and RANKL. J Biol Chem. 2008;283(36):24871–80.CrossRefPubMedPubMedCentral Lamothe B, et al. The RING domain and first zinc finger of TRAF6 coordinate signaling by interleukin-1, lipopolysaccharide, and RANKL. J Biol Chem. 2008;283(36):24871–80.CrossRefPubMedPubMedCentral
15.
18.
go back to reference Jeong SJ, et al. Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene. 2005;24(44):6719–28.CrossRefPubMed Jeong SJ, et al. Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene. 2005;24(44):6719–28.CrossRefPubMed
19.
go back to reference Mayo LD, The TDB, PTEN. Mdm2, p53 tumor suppressor–oncoprotein network. Biochem Sci. 2002;27(9):462–7.CrossRef Mayo LD, The TDB, PTEN. Mdm2, p53 tumor suppressor–oncoprotein network. Biochem Sci. 2002;27(9):462–7.CrossRef
20.
go back to reference Heckman CA, Mehew JM, Boxer LM. NF-κB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene. 2002;21(24):3898–908.CrossRefPubMed Heckman CA, Mehew JM, Boxer LM. NF-κB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene. 2002;21(24):3898–908.CrossRefPubMed
21.
go back to reference Kim SY, et al. Hydrogen peroxide controls Akt activity via ubiquitination/degradation pathways. Oncol Rept. 2011;26(6):1561–6. Kim SY, et al. Hydrogen peroxide controls Akt activity via ubiquitination/degradation pathways. Oncol Rept. 2011;26(6):1561–6.
22.
go back to reference Ling MT, et al. Id-1 expression promotes cell survival through activation of NF-kappaB signaling pathway in prostate cancer cells. Oncogene. 2003;22(29):4498–508.CrossRefPubMed Ling MT, et al. Id-1 expression promotes cell survival through activation of NF-kappaB signaling pathway in prostate cancer cells. Oncogene. 2003;22(29):4498–508.CrossRefPubMed
23.
go back to reference Pugazhenthi S, et al. Akt/protein kinase B Up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 2000;275(15):10761–6.CrossRefPubMed Pugazhenthi S, et al. Akt/protein kinase B Up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 2000;275(15):10761–6.CrossRefPubMed
24.
go back to reference Dey N, et al. TAK1 regulates NF-κB and AP-1 activation in airway epithelial cells following RSV infection. Virology. 2011;481(2):93–101.CrossRef Dey N, et al. TAK1 regulates NF-κB and AP-1 activation in airway epithelial cells following RSV infection. Virology. 2011;481(2):93–101.CrossRef
25.
go back to reference Gui T, et al. The roles of mitogen-activated protein kinase pathways in TGF-beta-induced epithelial-mesenchymal transition. J Signal Transduct. 2011;2012(4):289243. Gui T, et al. The roles of mitogen-activated protein kinase pathways in TGF-beta-induced epithelial-mesenchymal transition. J Signal Transduct. 2011;2012(4):289243.
26.
27.
go back to reference Wang WF, et al. Activation of the HPK1-dependent, stress-activated JNK pathway TAK1, a kinase mediator of TGF-β signal transduction. J Biol Chem. 1997;272(36):22771–5.CrossRefPubMed Wang WF, et al. Activation of the HPK1-dependent, stress-activated JNK pathway TAK1, a kinase mediator of TGF-β signal transduction. J Biol Chem. 1997;272(36):22771–5.CrossRefPubMed
28.
go back to reference Liu W, et al. Suppression of tumor cell proliferation by quinine via the inhibition of the tumor necrosis factor receptor-associated factor 6-AKT interaction. Mol Med Rep. 2016;14(3):2171–9.PubMed Liu W, et al. Suppression of tumor cell proliferation by quinine via the inhibition of the tumor necrosis factor receptor-associated factor 6-AKT interaction. Mol Med Rep. 2016;14(3):2171–9.PubMed
30.
go back to reference Bae-Jump VL, et al. Synergistic effect of rapamycin and Cis-platinum in endometrial cancer cells. Cancer. 2009;115(17):3887–96.CrossRefPubMed Bae-Jump VL, et al. Synergistic effect of rapamycin and Cis-platinum in endometrial cancer cells. Cancer. 2009;115(17):3887–96.CrossRefPubMed
31.
go back to reference Schnetzke U, et al. The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. J Cancer Res Clin Oncol. 2013;139(4):605–15.CrossRefPubMed Schnetzke U, et al. The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. J Cancer Res Clin Oncol. 2013;139(4):605–15.CrossRefPubMed
32.
go back to reference Martin A, et al. Lyn kinase controls TLR4-dependent IKK and MAPK activation modulating the activity of TRAF-6/TAK-1 protein complex in mast cells. Innate Immun. 2012;18(4):648–60.CrossRef Martin A, et al. Lyn kinase controls TLR4-dependent IKK and MAPK activation modulating the activity of TRAF-6/TAK-1 protein complex in mast cells. Innate Immun. 2012;18(4):648–60.CrossRef
33.
go back to reference Byrme AT, et al. Analysis of apoptosis in the preimplantion bovine embryo using TUNEL. J Reprod Fertil. 1999;117(1):97–105.CrossRef Byrme AT, et al. Analysis of apoptosis in the preimplantion bovine embryo using TUNEL. J Reprod Fertil. 1999;117(1):97–105.CrossRef
34.
go back to reference Zhu LP, et al. Effects of naringenin on inflammation in complete freund’s adjuvant-induced arthritis by regulating Bax/Bcl-2 balance. Inflammation. 2015;38(1):245–51.CrossRefPubMed Zhu LP, et al. Effects of naringenin on inflammation in complete freund’s adjuvant-induced arthritis by regulating Bax/Bcl-2 balance. Inflammation. 2015;38(1):245–51.CrossRefPubMed
35.
go back to reference Wang M, et al. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression. World J Surg Oncol. 2015;13:66.CrossRefPubMedPubMedCentral Wang M, et al. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression. World J Surg Oncol. 2015;13:66.CrossRefPubMedPubMedCentral
36.
go back to reference Dinio T, et al. Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum. Bioorg Med Chem. 2012;20(10):3292–7.CrossRefPubMedPubMedCentral Dinio T, et al. Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum. Bioorg Med Chem. 2012;20(10):3292–7.CrossRefPubMedPubMedCentral
37.
go back to reference Wang AL, et al. TRAF4 participates in Wnt/β-catenin signaling in breast cancer by upregulating β-catenin and mediating its translocation to the nucleus. Mol Cell Biochem. 2014;395(2):211–9.CrossRefPubMed Wang AL, et al. TRAF4 participates in Wnt/β-catenin signaling in breast cancer by upregulating β-catenin and mediating its translocation to the nucleus. Mol Cell Biochem. 2014;395(2):211–9.CrossRefPubMed
38.
go back to reference Mortensen SR, et al. Comparison of the in vitro sensitivity of rat acetylcholinesterase to chlorpyrifos-oxon: what do tissue IC50 values represent? Toxicol Appl Pharmacol. 1998;148(1):46–9.CrossRefPubMed Mortensen SR, et al. Comparison of the in vitro sensitivity of rat acetylcholinesterase to chlorpyrifos-oxon: what do tissue IC50 values represent? Toxicol Appl Pharmacol. 1998;148(1):46–9.CrossRefPubMed
39.
go back to reference Karbwang J, et al. Pharmacokinetics of quinine, quinidine and cinchonine when given as combination. Southeast Asian J. Trop. Med. Public Health. 1993;23(4):773–6. Karbwang J, et al. Pharmacokinetics of quinine, quinidine and cinchonine when given as combination. Southeast Asian J. Trop. Med. Public Health. 1993;23(4):773–6.
40.
go back to reference Chen H, et al. Akt activation and inhibition of cytochrome C release: mechanistic insights into leptin-promoted survival of type II alveolar epithelial cells. J Cell Biochem. 2015;116(10):2313–24.CrossRefPubMed Chen H, et al. Akt activation and inhibition of cytochrome C release: mechanistic insights into leptin-promoted survival of type II alveolar epithelial cells. J Cell Biochem. 2015;116(10):2313–24.CrossRefPubMed
41.
go back to reference Dinicola S, et al. Multiwalled carbon nanotube buckypaper induces cell cycle arrest and apoptosis in human leukemia cell lines through modulation of AKT and MAPK signaling pathways. Toxicol In Vitro. 2015;29(7):1298–308.CrossRefPubMed Dinicola S, et al. Multiwalled carbon nanotube buckypaper induces cell cycle arrest and apoptosis in human leukemia cell lines through modulation of AKT and MAPK signaling pathways. Toxicol In Vitro. 2015;29(7):1298–308.CrossRefPubMed
42.
go back to reference Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003;546(1):108–12.CrossRefPubMed Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003;546(1):108–12.CrossRefPubMed
43.
go back to reference Carpten JD, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448(7152):439–44.CrossRefPubMed Carpten JD, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448(7152):439–44.CrossRefPubMed
44.
go back to reference Kim H, et al. Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells. Breast Cancer Res Treat. 2008;112(2):287–96.CrossRefPubMed Kim H, et al. Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells. Breast Cancer Res Treat. 2008;112(2):287–96.CrossRefPubMed
46.
go back to reference Li Y, et al. Curcumin inhibits human Non-small cell lung cancer A549 cell proliferation through regulation of Bcl-2/Bax and cytochrome. Asian Pac J Cancer Prev. 2013;14(8):4599–602.CrossRefPubMed Li Y, et al. Curcumin inhibits human Non-small cell lung cancer A549 cell proliferation through regulation of Bcl-2/Bax and cytochrome. Asian Pac J Cancer Prev. 2013;14(8):4599–602.CrossRefPubMed
47.
go back to reference Luo S, Rubinsztein DC. Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-Xl. Cell Death Differ. 2010;17(2):268–77.CrossRefPubMed Luo S, Rubinsztein DC. Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-Xl. Cell Death Differ. 2010;17(2):268–77.CrossRefPubMed
48.
go back to reference Pettersson F, Dalgleish AG, Bissonnette RP. Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer. 2002;87(5):555–61.CrossRefPubMedPubMedCentral Pettersson F, Dalgleish AG, Bissonnette RP. Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer. 2002;87(5):555–61.CrossRefPubMedPubMedCentral
49.
go back to reference Pattingre S, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122(6):927–39.CrossRefPubMed Pattingre S, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122(6):927–39.CrossRefPubMed
50.
go back to reference Linseman DA, et al. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci. 2004;24(44):9993–10002.CrossRefPubMed Linseman DA, et al. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci. 2004;24(44):9993–10002.CrossRefPubMed
51.
go back to reference Kluck RM, et al. The release of Cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275(5303):1132–6.CrossRefPubMed Kluck RM, et al. The release of Cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275(5303):1132–6.CrossRefPubMed
52.
53.
go back to reference Ye H, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature. 2002;418(6896):443–7.CrossRefPubMed Ye H, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature. 2002;418(6896):443–7.CrossRefPubMed
54.
go back to reference Fukushima T, et al. Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses. Proc Natl Acad Sci U S A. 2007;104(15):6371–6.CrossRefPubMedPubMedCentral Fukushima T, et al. Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses. Proc Natl Acad Sci U S A. 2007;104(15):6371–6.CrossRefPubMedPubMedCentral
Metadata
Title
Cinchonine induces apoptosis of HeLa and A549 cells through targeting TRAF6
Authors
Yonghao Qi
Ambara R. Pradipta
Miao Li
Xuan Zhao
Lulu Lu
Xuegang Fu
Jing Wei
Richard P. Hsung
Katsunori Tanaka
Lijun Zhou
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-017-0502-8

Other articles of this Issue 1/2017

Journal of Experimental & Clinical Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine